v3.25.1
Organization and Nature of Business
 3 Months Ended
Mar. 31, 2025
Organization and Nature of Business [Abstract]  
Organization and nature of business
(1)Organization and nature of business

 

The condensed consolidated financial statements of OSR Holdings, Inc. (the “Company” or the “Parent”) and its subsidiaries (collectively, the “Group”) for the period ended March 31, 2025 were authorized for issuance in accordance with a resolution of the directors meeting on May 7, 2025. The registered office is located at 37-36 Hoedong-gil, Paju-si, Gyeongi-do, Republic of Korea.

 

The Company is a global life sciences holding company based in South Korea and is actively engaging in drug development, dedicating to advance healthcare outcome and driving social progress. Through open innovation and responsible investment, the Company aims to make a lasting impact across the industry as well as our society. With a strong focus on oncology and immunology, the Company’s mission is to build a robust portfolio of ventures, bringing innovative and transformative therapies to market.

 

Details of shareholders as of March 31, 2025 are as follows:

 

Name of Shareholder  Number of
ordinary share		   Percentage of
ownership		 
Bellevue Global Life Sciences Investors LLC   1,332,500    6.91%
Bellevue Capital Management Europe AG   8,612,634    44.68%
Bellevue Capital Management LLC   3,123,970    16.21%
Duksung Co.,Ltd.   1,420,215    7.37%
Others   4,787,659    25.68%
Total   19,276,978    100.00%

 

Details of investments in subsidiaries as of March 31, 2025 are as follows:

 

Name of subsidiary  Share capital   Percentage of ownership   Principal activities  Country of
incorporation
VAXIMM AG (“VAXIMM”)   1,091,203,754    100.00%  Biotech (drug development)  Switzerland
RMC Co., Ltd. (“RMC”)   35,000,000    100.00%  Medical device distribution  Republic of Korea
Darnatein Co., Ltd. (“Darnatein”)   6,466,667,000    100.00%  Biotech (drug development)  Republic of Korea
OSR Holdings, Inc.   2,826,969    100.00%  SPAC  The United States

 

Key financial information of the subsidiaries at March 31, 2025 are as follows :

 

Name of subsidiary  Asset   Liability   Equity   Sales   Net Income
(loss)		 
VAXIMM AG  $910,415   $386,254   $524,161   $
-
   $(78,609)
RMC Co.,Ltd   2,040,181    1,568,695    471,486    761,272    (211,541)
Darnatein Co.,Ltd   110,171    678,651    (568,481)   
-
    (141,742)
OSR Holdings, Inc.   1,687,119    10,071,814    (8,384,695)   
-
    
-
 

Summaries of entities, which are newly included in consolidation scope for the periods ended March 31, 2025 and 2024 are as follows:

 

For the year ended March 31, 2025
Name of subsidiary  Reason  Type of purchase consideration
OSR Holdings, Inc.  Acquisition (*1)  Equity swap with shares of the Parent and OSR inc.’s share

 

(*1)The Parent acquired subsidiary in February 2025 and accounted for the acquisitions at March 31, 2025, which is deemed the acquisition date.